FOR IMMEDIATE DISTRIBUTION
Woodland and SBH Sciences Announce New Incubator Model
to support IND-enabling Preclinical Efficacy Studies for Novel Oncology Molecules
(Worcester, MA and Natick, MA) October 10, 2012. Woodland Oncology Services and SBH Sciences Inc. announce the next step in their partnership: "Your Oncology Incubator". This new offering builds upon the expertise and experience that both SBH and Woodland bring to advancing molecules toward clinical development. From the biotech side, SBH has collaborated closely with various companies to successfully advance 3 molecules from early testing to clinical trials in the past 5 years. Woodland's founder, with experience in both large and small pharma companies, has participated in the preclinical efficacy testing of numerous candidates with two compounds reaching the market, telaprevir and celecoxib. Several others are in clinical trials or have reached clinical candidate nomination.
The process starts with the identification of a novel molecule brought to Woodland-SBH Sciences for idea realization. This includes biological support for lead optimization and SAR studies, and pharmacological modeling starting with in vitro assays, followed by a seamless translation to in vivo state-of-the-art models, and ending with ex vivo primary human patient tumor studies. Your drug may also be tested in combination with any of 29 approved drugs currently available through SBH Sciences or clinical stage compounds available commercially.
Effective immediately, Woodland-SBH Sciences is accepting proposals for new molecule testing. Efficacy studies will culminate with an IND-enabling package ready for regulatory submission. As your study is progressed, data obtained may allow the company and the Incubator to apply for government funding or seek additional sponsorships from the venture community.
The Oncology Incubator will test the new drug in a series of assays leading up to tests in primary patient tumors meant to give you a preview of the experience you will face as you move into the clinic. These preclinical trials will help to identify responder and non-responder profiles, including the identification of responder signatures or predictive biomarkers, and is intended to provide an extra measure of confidence as you move into early clinical development.
Michael Briggs, PhD, President of Woodland Pharmaceuticals, said: "We will first evaluate the molecule properties, your early data and IP estate, and then take the best ideas and molecules and qualify them with in vitro assays at SBH. We then move smoothly and rapidly into Woodland for xenograft models and more complex in vivo studies, including PK and PK/PD modeling. We will draw on SBH Sciences's expertise in making antibodies and running biomarker studies to assist with target activity marker analyses. Taking ideas and making them into drugs is what this next evolution in the development of the Woodland-SBH Sciences partnership entails."
Raphael Nir, PhD President of SBH Sciences, said of becoming an incubator, "The most rapid and efficient path to the IND starts with the preclinical in vitro and animal model studies. Our aligned discovery capabilities provide complementary expertise that will streamline the development effort, enhance innovation, and reduce development time. We are constantly expanding our services and this collaboration will allow us to help our customers reach Phase I trials, primarily in oncology and inflammation. It is our privilege to work with Dr. Michael Briggs and his dedicated and knowledgeable team".
Woodland-SBH Sciences as an "Oncology Incubator"
- A home for your novel drug ideas and your molecules
- Evaluation of your molecules against current therapies and other drugs in clinical trials
- A shared risk opportunity to rapidly proceed to preclinical Proof-of-Concept
- Our data packages will better Enable Grant Applications – SBIR/STTR
- Our efficacy studies will provide direct confirmation of your ideas and prove that your molecules can compete in the clinic to Enable Funding Opportunities
- We propel your research from a good idea to a well-characterized molecule moving assertively toward the Clinic
About Woodland Oncology Services:
Woodland Oncology Services provides experience and a proven history of oncology expertise in xenograft studies and in vivo capabilities including drug resistant tumor models. These skills in combination with primary patient tumor resources will bring together the different phases of the preclinical process under one virtual roof.
For more information, please visit our website: www.woodlandoncologyservices.com
Or follow us on LinkedIn at http://www.linkedin.com/company/woodland-pharmaceuticals-llc or Twitter at http://twitter.com/WoodlandPharma.
About SBH Sciences:
SBH Sciences is known for their in vitro work in anti-cancer and anti-inflammation including cytokines and biomarkers. With over 180 Human Cancer Cells and previous experience with combination drug testing and evaluation, SBH Sciences is a key in the incubator model. The invaluable services and help from SBH Sciences have led multiple companies to reach the clinic. For a list of the companies and a link to their website, please see below.
For more information, please visit: www.sbhsciences.com
Or Follow us on LinkedInhttp://www.linkedin.com/company/sbh-sciences or Twitter at http://twitter.com/SBHSciences.
Companies that have reached the clinic with the help of SBH Sciences:
Galectin Therapeutics www.galectintherapeutics.com
President and CSO
Raphael Nir, Ph.D., 508-650-6218 x 214
Woodland Oncology Services
President and CSO
Michael R. Briggs, Ph.D., 617-416-2522